Read Lab

Glioblastomas (GBM), the most common primary brain tumors, are caused by mutations that perturb developmental and homeostatic processes in glial progenitor cells and/or neural stem cells in the central nervous system (CNS). Our goal is to determine how aspects of GBM cell biology and genetics can be effectively targeted to actively eliminate these tumor cells in the brain. To this end, our research addresses a number of outstanding questions in the field. For example, how do mutations in cell signaling pathways promote malignancy? How are other pathways or mutations involved in GBM? Which genes specifically control GBM cell invasion? Which glial cells and/or neural stem cell types in the CNS undergo neoplastic transformation and why? How do cell-cell interactions in the brain contribute to GBM tumorigenesis? Can the molecular pathways driving GBM be effectively targeted for therapeutic benefit?
 

download.jpg

Glioblastoma

GBM39  DMSO 18 hr AO-EB 40x 1 redo A slc
Slide I Wide Angle A copy.tiff

Research Program

Our research program uses a multidisciplinary approach to analyze the function of developmental cell-signaling pathways in tumorigenesis. Our research projects now focus all on mammalian brain tumor model systems, including Drosophila melanogaster and mouse genetic models of GBM, primary patient-derived human GBM stem cells, and human iPS cell-derived brain organoid ('mini-brain') models. Our current projects focuses on the functional role of mutant variants in receptor tyrosine kinases (RTKs), such as EGFR and MET, and their downstream signaling pathways in tumor initiation and progression.


Through our efforts, we identified new RTK effectors that regulate tumor cell proliferation and invasion as well as tumor-microenvironment interactions. Our work includes new clinical trials that target effectors of RTK signaling in GBM, including the YAP and TAZ transcription factors. We have also discovered several mutations in the MET tyrosine kinase which may serve as effective therapeutic targets for adult and pediatric GBM. Ongoing projects in our lab also include research on the role of RTK effector pathways in sex differences in tumor development and in cell-cell interactions in the tumor microenvironment.

Our research program is aided by productive collaborations with other neuro-oncology researchers in the Departments of Neurosurgery, Pediatrics, Human Genetics, Pathology, and Hematology and Medical Oncology, including clinical neurosurgical and neuropathology faculty. We welcome young scientists who seek to enter this dynamic field. Trainees in our lab will have opportunities to work with all of our brain tumor model systems, perform drug testing experiments in pre-clinical paradigms, interface with clinical neuro-oncology faculty, and advocate for patient outreach and education.

We are located in the Department of Pharmacology and Chemical Biology at Emory University School of Medicine in Atlanta, Georgia. We are open to students and postdoctoral fellows interested in joining our research team. Dr. Read is a full member of the Neuroscience and Molecular Systems Pharmacology Graduate Programs, and has to trained students in other graduate programs, such as Cancer Biology.

We are proud supporters of diversity and inclusion in scientific research and training. Our lab welcomes members from all orientations, backgrounds, and nationalities to bring their passion and life experience to our work together to advance discovery and development of new therapies and therapeutic targets for adult and pediatric brain tumors.  

We are also especially interested in trainees seeking to expand research at the interface of public health and community outreach in relation to brain tumors and brain tumor patients.


Contact:  renee.read@emory.edu,  404-727-5985,  1510 Clifton Rd, Atlanta, GA 30322